Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  Mainous, Arch G ^a,b   Tanner, Rebecca J ^a   Shorr, Ronald I ^b   Limacher, Marian C ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Cardiovascular diseases; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG USE; EDUCATION; FEMALE; FRAMINGHAM RISK SCORE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE ACCESS; HEALTH INSURANCE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICIAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RACE; SECONDARY PREVENTION; UNITED STATES; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; MEDICATION COMPLIANCE; MIDDLE AGED; RISK ASSESSMENT; SELF REPORT; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; SELF REPORT; UNITED STATES;

EID: 84924954268     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000989     Document Type: Article

References (32)

1. Murphy SL, Xu JQ, Kochanek KD. Deaths: Final Data for 2010. National Vital Statistics Reports; vol. 61, no 4. Hyattsville, MD: National Center for Health Statistics; 2013.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
3. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;136:161-172.
4. US Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-160.
5. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106:388-391.
6. Nemerovski CW, Salinitri FD, Morbitzer KA, Moser LR. Aspirin for prevention of cardiovascular disease events. Pharmacotherapy. 2012;32:1020-1035.
7. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113:2363-2372.
8. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
9. George MG, Tong X, Sonnenfeld N, Hong Y. Recommended use of aspirin and other antiplatelet medications among adults: National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2012;61:8-11.
10. VanWormer JJ, Greenlee RT, McBride PE, Peppard PE, Malecki KC, Che J, Nieto FJ. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract. 2012;61:525-532.
11. US Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: recommendation statement. Am Fam Physician. 2011;83:441-443.
12. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694-2701.
13. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA; American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:776S-814S.
14. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
15. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753.
16. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162:e2.
17. Lin KJ, De Caterina R, García Rodríguez LA. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study. Circ Cardiovasc Qual Outcomes. 2014;7:70-77.
18. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16:1945-1953.
19. Cea Soriano L, Rodríguez LA. Risk of upper gastrointestinal bleeding in a Cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol. 2010;1:126.
20. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245.
21. Jones JB, Shah NR, Bruce CA, Stewart WF. Meaningful use in practice using patient-specific risk in an electronic health record for shared decision making. Am J Prev Med. 2011;40:S179-S186.
22. Ross JS, Bradley EH, Busch SH. Use of health care services by lower-income and higher-income uninsured adults. JAMA. 2006;295:2027-2036.
23. DeVoe JE, Fryer GE, Phillips R, Green L. Receipt of preventive care among adults: insurance status and usual source of care. Am J Public Health. 2003;93:786-791.
24. Ayanian JZ, Weissman JS, Schneider EC, Ginsburg JA, Zaslavsky AM. Unmet health needs of uninsured adults in the United States. JAMA. 2000;284:2061-2069.
25. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2:e353.
26. Yoon PW, Tong X, Schmidt SM, Matson-Koffman D. Clinical preventive services for patients at risk for cardiovascular disease, National Ambulatory Medical Care Survey, 2005-2006. Prev Chronic Dis. 2011;8:A43.
27. Ross CE, Wu C-L. The links between education and health. Am Sociol Rev. 1995;60:719-745.
28. Borrell LN, Dallo F, White K. Education and diabetes in a racially and ethnically diverse population. Am J Public Health. 2006;96:1637-1642.
29. Kimbro RT, Bzostek S, Goldman N, Rodriguez G. Race, ethnicity, and the education gradient in health. Health Aff. 2008;27:361-372.
30. Telfair J, Shelton TL. Educational attainment as a social determinant of health. N C Med J. 2012;73:358-365.
31. Newell SA, Girgis A, Sanson-Fisher RW, Savolainen NJ. The accuracy of selfreported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am J Prev Med. 1999;17:211-229.
32. US Preventive Services Task Force. Routine aspirin or nonsteroidal antiinflammatory drugs for the primary prevention of colorectal cancer: US Preventive Services Task Force recommendation. Ann Intern Med. 2007;146:361-364.